XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative (NQ:XOMAO)

25.41 +0.06 (+0.24%)

Streaming Delayed Price Updated: 2:35 PM EST, Nov 21, 2025 Add to My Watchlist

Price and Volume

Volume	2,445
Open	25.40
Bid (Size)	25.29 (200)
Ask (Size)	25.44 (100)
Prev. Close	25.35
Today's Range	25.28 - 25.44
52wk Range	23.32 - 25.76
Shares Outstanding	N/A
Dividend Yield	8.23%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

November 21, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

November 12, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Performance

YTD	-0.8%	-0.8%
1 Month	-0.4%	-0.4%
3 Month	+0.1%	+0.1%
6 Month	+1.2%	+1.2%
1 Year	+0.3%	+0.3%

More News

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

October 17, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

October 02, 2025

From XOMA Royalty Corporation; LAVA Therapeutics

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

September 22, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

September 17, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 03, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

August 20, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

August 04, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

August 04, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

June 27, 2025

From XOMA Royalty Corporation; Turnstone Biologics Corp.

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

June 18, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 27, 2025

From XOMA Royalty Corporation; BioInvent

Via GlobeNewswire

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

May 13, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 07, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

April 14, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

April 02, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

March 20, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

March 17, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Present at Investor Conferences in March

February 24, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 04, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

December 19, 2024

From XOMA Royalty Corporation

Via GlobeNewswire

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

December 02, 2024

From XOMA Corporation

Via GlobeNewswire

Frequently Asked Questions

Is XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative publicly traded?

Yes, XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is publicly traded.

What exchange does XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative trade on?

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative trades on the Nasdaq Stock Market

What is the ticker symbol for XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative?

The ticker symbol for XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is XOMAO on the Nasdaq Stock Market

What is the current price of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative?

The current price of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is 25.41

When was XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative last traded?

The last trade of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative was at 11/21/25 02:35 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.